EUCTR2015-001343-37-CZActive, not recruitingPhase 1
A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm EvolocumabAdministration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Amgen Inc
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Male or female, = 18 years of age at signing of informed consent.
- •- Subject has been receiving regular apheresis for LDL-C lowering for at least 3 months immediately prior to lipid screening (per subject or physician report), has a treatment goal of LDL-C < 100 mg/dL (2.6 mmol/L) according to the physician managing the subject’s hypercholesterolemia, and has been receiving LDL-C apheresis during the last = 4 weeks prior to lipid screening at regular QW or Q2W schedule and with no changes in apheresis type.
- •- Subject is receiving lipid-lowering pharmacological background therapy which includes a high-intensity statin dose (moderate-intensity statin dose with attestation that a higher dose is not appropriate for the subject) per Appendix D, unless the subject has a history of statin intolerance.
- •- Pre-apheresis LDL-C is = 100 mg/dL (= 2.6 mmol/L) and = 190 mg/dL (= 4.9 mmol/L) at screening.
- •- Fasting triglycerides = 400 mg/dL (4.5 mmol/L) at screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
Exclusion Criteria
- •- Known homozygous familial hypercholesterolemia.
- •- Missing any apheresis session is medically contraindicated or inappropriate based on the opinion of the investigator.
- •- Stopping apheresis would be inappropriate in the opinion of the investigator even if LDL-C is controlled to < 100 mg/dL with other therapies (eg, subject with Lp(a) > 60 mg/dL and for whom investigator would continue apheresis for Lp(a) reduction even with LDL-C <100 mg/dL).
- •- Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization.
- •- Known active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction (except diabetes) or receiving renal replacement therapy.
- •- Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) > 180 mmHg or diastolic blood pressure (DBP) > 110 mmHg.
- •- Subject has taken a cholesterylester transfer protein (CETP) inhibitor such as anacetrapib, dalcetrapib or evacetrapib in the last 12 months, or mipomersen or lomitapide in the last 5 months prior to LDL-C screening.
- •- Subject has previously received fully human anti-PCSK9 antibody therapy (eg, evolocumab) within < 12 weeks prior to lipid screening or has received any other therapy to inhibit PCSK9 at any time.
- •- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s) or planning to receive other investigational procedures while participating in this study.
- •- Female subject who has (1) not used (an) acceptable method(s) of birth control for at least 1 month prior to screening and/or (2) is not willing to inform her partner of her participation in this clinical study and to use such (an) acceptable method(s) of effective birth control during treatment with IP
- •(evolocumab) and for an additional 15 weeks after the end of treatment with IP (evolocumab), unless the female subject is permanently sterilized or postmenopausal (see protocol);
- •- Subject is pregnant or breast feeding, or planning to become pregnant or planning to breastfeed during treatment with IP (evolocumab) and/or within 15 weeks after the end of treatment with IP (evolocumab).
- •-Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 1 year prior to screening.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study of Evolocumab in Patients Undergoing Low-Density Lipoprotein ApheresisHypercholesterolemiaEUCTR2015-001343-37-DEAmgen Inc50
Active, not recruiting
Phase 1
Study of Evolocumab in Patients Undergoing Low-Density Lipoprotein ApheresisMedDRA version: 20.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersHypercholesterolemiaEUCTR2015-001343-37-ITAMGEN INC.50
Active, not recruiting
Phase 1
Study of Evolocumab in Patients Undergoing Low-Density Lipoprotein ApheresisHypercholesterolemiaEUCTR2015-001343-37-ESAmgen Inc50
Completed
Phase 3
A trial to study the efficacy and safety of PDM011011 capsules in comparison with metformin in type 2 diabetic patients.CTRI/2013/01/003308Piramal Healthcare Limited150
Active, not recruiting
Phase 1
Clinical trial comparing Lipegfilgrastim to Filgrastim in Pediatric Patients Diagnosed with Ewing Family of Tumors or Rhabdomyosarcoma Receiving Chemotherapy.eutropenia in pediatric patients diagnosed with Ewing family of Tumors or rhabdomyosarcoma receiving chemotherapyMedDRA version: 18.1Level: PTClassification code 10029354Term: NeutropeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 18.1Level: PTClassification code 10016288Term: Febrile neutropeniaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2015-000087-34-DEMerckle GmbH42